Nucleophosmin mutations in De novo adult acute myeloid leukemia and its prognostic impact /
Lamiaa Nabih Helal Elfadali
Nucleophosmin mutations in De novo adult acute myeloid leukemia and its prognostic impact / دراسة تكرار طفرة جين النيوكليوفوزمين فى حالات سرطان الدم الميلودى الحاد الجديدة لدى البالغين Lamiaa Nabih Helal Elfadali ; Supervised Khaled Mostafa Aboulenein , Naglaa Mostafa Hassan Ahmed , Raafat Mohammad Abdelfattah - Cairo : Lamiaa Nabih Helal Elfadali , 2020 - 143 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology
Aim:To evaluate the frequency of NPM mutation A in denovo adult AML and to evaluate its relation with clinical and laboratory parameters and with response to treatment. Patients and Methods: 89 patients were included in our study, taking BM samples, RNA extraction and quantitative RT-PCR were done to detect the frequency of NPM1 mutation A. Results:We found NPM1 mutation in 33/89 (37.1) AML patients of which NPM mutation A was found in 6/33 (18.1%) NPM mutated AML patients and was 6/89 (6.7%) of AML patients. 24/33 (72.7%) NPM mutated patients were died before day 28 of treatment. 9/33 (27.3%) NPM mutant patients achieved CR. 5/6 (83.3%) NPM mutation A patients died before D28 of treatment and 1/6 (6.7%) NPM mutation A patient achieve CR with no statistically significance. Conclusions:We found that frequency of NPM gene mutation was 37% of AML patients and NPM gene mutation A was 18% of NPM1 mutation and 6.7 of AML patients
Activities of daily living (ADL) Acute myeloid leukemia Nucleophosmin gene mutation
Nucleophosmin mutations in De novo adult acute myeloid leukemia and its prognostic impact / دراسة تكرار طفرة جين النيوكليوفوزمين فى حالات سرطان الدم الميلودى الحاد الجديدة لدى البالغين Lamiaa Nabih Helal Elfadali ; Supervised Khaled Mostafa Aboulenein , Naglaa Mostafa Hassan Ahmed , Raafat Mohammad Abdelfattah - Cairo : Lamiaa Nabih Helal Elfadali , 2020 - 143 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology
Aim:To evaluate the frequency of NPM mutation A in denovo adult AML and to evaluate its relation with clinical and laboratory parameters and with response to treatment. Patients and Methods: 89 patients were included in our study, taking BM samples, RNA extraction and quantitative RT-PCR were done to detect the frequency of NPM1 mutation A. Results:We found NPM1 mutation in 33/89 (37.1) AML patients of which NPM mutation A was found in 6/33 (18.1%) NPM mutated AML patients and was 6/89 (6.7%) of AML patients. 24/33 (72.7%) NPM mutated patients were died before day 28 of treatment. 9/33 (27.3%) NPM mutant patients achieved CR. 5/6 (83.3%) NPM mutation A patients died before D28 of treatment and 1/6 (6.7%) NPM mutation A patient achieve CR with no statistically significance. Conclusions:We found that frequency of NPM gene mutation was 37% of AML patients and NPM gene mutation A was 18% of NPM1 mutation and 6.7 of AML patients
Activities of daily living (ADL) Acute myeloid leukemia Nucleophosmin gene mutation